Effect of time restricted eating versus current practice in dietetics on glycaemic control and cardio-metabolic outcomes in individuals at risk of developing type 2 diabetes: Protocol for a multi-centre, parallel group, non-inferiority, randomised controlled trial

IF 2 3区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Rasha Charrouf , Evelyn B. Parr , Amy T. Hutchison , Steve A. Flint , Xiao Tong Teong , Gary Wittert , Andrew D. Vincent , Leah Brennan , Brooke L. Devlin , John A. Hawley , Leonie K. Heilbronn
{"title":"Effect of time restricted eating versus current practice in dietetics on glycaemic control and cardio-metabolic outcomes in individuals at risk of developing type 2 diabetes: Protocol for a multi-centre, parallel group, non-inferiority, randomised controlled trial","authors":"Rasha Charrouf ,&nbsp;Evelyn B. Parr ,&nbsp;Amy T. Hutchison ,&nbsp;Steve A. Flint ,&nbsp;Xiao Tong Teong ,&nbsp;Gary Wittert ,&nbsp;Andrew D. Vincent ,&nbsp;Leah Brennan ,&nbsp;Brooke L. Devlin ,&nbsp;John A. Hawley ,&nbsp;Leonie K. Heilbronn","doi":"10.1016/j.cct.2024.107696","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Time restricted eating (TRE) is a dietary strategy that may improve metabolic health. However, no studies have compared TRE with current practice (CP) in dietetics.</p></div><div><h3>Hypothesis</h3><p>TRE will not be inferior to CP to improve glycaemic control in individuals at risk of type 2 diabetes (T2D).</p></div><div><h3>Methods</h3><p>This parallel group, randomised, non-inferiority, controlled trial randomised 247 participants by site and glycated haemoglobin (HbA1c) into TRE or CP (1:1) for 12 months. Participants were aged 35–70 years, with a body mass index (BMI) &gt;25 but &lt;45 kg/m<sup>2</sup>, and score ≥15 on the Australian type 2 diabetes risk (AUSDRISK) assessment, without a diagnosis of T2D. Study visits were balanced between groups and all participants received five consultations at 0, 0.5, 1, 2 and 3 months. TRE followed a self-selected 9 h eating window (≥0600 and ≤1900), whereas CP followed Australian dietary guidelines.</p></div><div><h3>Outcomes</h3><p>The primary endpoint is the estimate of group mean difference (TRE vs CP) of HbA1c at 4 months in a covariate linear regression adjusting for stratification factors and sex. Secondary efficacy outcomes at 4 and 12 months are changes in fasting glucose, fasting insulin, HOMA-IR and nocturnal glucose by continuous glucose monitor incremental area under the curve and change in HbA1c at 12 months. Other endpoints are exploratory and will not be adjusted for multiplicity.</p></div><div><h3>Conclusions</h3><p>We will determine whether TRE is an alternate strategy to current practice in dietetics to improve glucose control.</p><p><strong>Trial registration:</strong> <span><span>NCT04762251</span><svg><path></path></svg></span>; 21 Feb 2021.</p></div>","PeriodicalId":10636,"journal":{"name":"Contemporary clinical trials","volume":"146 ","pages":"Article 107696"},"PeriodicalIF":2.0000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1551714424002799/pdfft?md5=acd72838f482adbb9b38430b3eb361a6&pid=1-s2.0-S1551714424002799-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contemporary clinical trials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1551714424002799","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Time restricted eating (TRE) is a dietary strategy that may improve metabolic health. However, no studies have compared TRE with current practice (CP) in dietetics.

Hypothesis

TRE will not be inferior to CP to improve glycaemic control in individuals at risk of type 2 diabetes (T2D).

Methods

This parallel group, randomised, non-inferiority, controlled trial randomised 247 participants by site and glycated haemoglobin (HbA1c) into TRE or CP (1:1) for 12 months. Participants were aged 35–70 years, with a body mass index (BMI) >25 but <45 kg/m2, and score ≥15 on the Australian type 2 diabetes risk (AUSDRISK) assessment, without a diagnosis of T2D. Study visits were balanced between groups and all participants received five consultations at 0, 0.5, 1, 2 and 3 months. TRE followed a self-selected 9 h eating window (≥0600 and ≤1900), whereas CP followed Australian dietary guidelines.

Outcomes

The primary endpoint is the estimate of group mean difference (TRE vs CP) of HbA1c at 4 months in a covariate linear regression adjusting for stratification factors and sex. Secondary efficacy outcomes at 4 and 12 months are changes in fasting glucose, fasting insulin, HOMA-IR and nocturnal glucose by continuous glucose monitor incremental area under the curve and change in HbA1c at 12 months. Other endpoints are exploratory and will not be adjusted for multiplicity.

Conclusions

We will determine whether TRE is an alternate strategy to current practice in dietetics to improve glucose control.

Trial registration: NCT04762251; 21 Feb 2021.

限时进食与现行营养学实践对 2 型糖尿病高危人群血糖控制和心血管代谢结果的影响:多中心、平行分组、非劣效随机对照试验方案
背景限时进食(TRE)是一种可改善代谢健康的饮食策略。方法这项平行分组、随机、非劣效对照试验将 247 名参与者按地点和糖化血红蛋白(HbA1c)随机分为 TRE 或 CP(1:1),为期 12 个月。参与者年龄在 35-70 岁之间,体重指数 (BMI) 为 25-45 kg/m2,澳大利亚 2 型糖尿病风险评估 (AUSDRISK) 得分≥15 分,未确诊为 2 型糖尿病。研究访问在各组之间均衡进行,所有参与者都在 0、0.5、1、2 和 3 个月时接受了五次咨询。结果主要终点是对分层因素和性别进行协变量线性回归调整后,4 个月时各组 HbA1c 平均差异(TRE vs CP)的估计值。4 个月和 12 个月时的次要疗效结果是空腹血糖、空腹胰岛素、HOMA-IR 和夜间血糖的变化(通过连续血糖监测仪的曲线下增量面积),以及 12 个月时 HbA1c 的变化。结论我们将确定 TRE 是否是当前营养学实践中改善血糖控制的替代策略:试验注册:NCT04762251;2021 年 2 月 21 日。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.70
自引率
4.50%
发文量
281
审稿时长
44 days
期刊介绍: Contemporary Clinical Trials is an international peer reviewed journal that publishes manuscripts pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted should appeal to a readership drawn from disciplines including medicine, biostatistics, epidemiology, computer science, management science, behavioural science, pharmaceutical science, and bioethics. Full-length papers and short communications not exceeding 1,500 words, as well as systemic reviews of clinical trials and methodologies will be published. Perspectives/commentaries on current issues and the impact of clinical trials on the practice of medicine and health policy are also welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信